1. Home
  2. ACOG vs TNXP Comparison

ACOG vs TNXP Comparison

Compare ACOG & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alpha Cognition Inc.

ACOG

Alpha Cognition Inc.

HOLD

Current Price

$8.52

Market Cap

185.1M

Sector

N/A

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$11.26

Market Cap

199.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACOG
TNXP
Founded
2000
2007
Country
Canada
United States
Employees
71
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.1M
199.7M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
ACOG
TNXP
Price
$8.52
$11.26
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$16.00
N/A
AVG Volume (30 Days)
100.6K
505.8K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.75
EPS
N/A
N/A
Revenue
N/A
$13,107,000.00
Revenue This Year
$139.22
$558.11
Revenue Next Year
$134.48
$38.29
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.85
52 Week Low
$4.50
$9.40
52 Week High
$10.10
$69.65

Technical Indicators

Market Signals
Indicator
ACOG
TNXP
Relative Strength Index (RSI) 53.53 50.95
Support Level $5.27 $10.03
Resistance Level $9.04 $13.18
Average True Range (ATR) 0.86 0.80
MACD -0.05 0.09
Stochastic Oscillator 46.33 56.48

Price Performance

Historical Comparison
ACOG
TNXP

About ACOG Alpha Cognition Inc.

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: